TARGETWATCH
BABavarian Nordic
Bavarian Nordic
Seneste kurs
180,00 DKK
22.7.2026
Seneste
250,00 DKK
+38.89%
Opside
BAVA
3 mdr.+38,89%1 kursmål
6 mdr.+36,11%5 kursmål
1 år+35,55%7 kursmål
Max 7 kursmål
Nordea
SundhedBiotechnology

Om selskabet

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Yahoo Finance

Seneste kursmål

Kursmål
250,00 DKK
Opside
+38,89%
Seneste kurs180,00 DKK

Flere kursmål for Bavarian Nordic

Analytiker
Dato
Jul 9
Kursmål
250,00 DKK

Analytiker
Dato
Feb 20
Kursmål
139,99 DKK

Analytiker
Dato
Feb 17
Kursmål
280,00 DKK

Analytiker
Dato
Feb 3
Kursmål
275,00 DKK

Analytiker
Dato
Jan 28
Kursmål
280,00 DKK

Analytiker
Dato
Nov -25
Kursmål
250,00 DKK

Analytiker
Dato
Aug -25
Kursmål
233,00 DKK